Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is advancing its proprietary multiple sclerosis (MS) therapy candidate, LUCID-MS, into patient-focused studies following favorable Phase 1 clinical data. The company reported that Phase 1 studies in healthy volunteers demonstrated a favorable safety profile and that the therapy was generally well tolerated, supporting progression to the next stage of clinical development.
In April 2026, Quantum BioPharma submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for LUCID-MS, a step that paves the way for a planned Phase 2 clinical trial in people living with multiple sclerosis. LUCID-MS is designed to target demyelination and protect or restore myelin integrity, offering a differentiated, potentially first-in-class approach. Unlike existing MS therapies that primarily rely on immune modulation, LUCID-MS aims to directly address myelin loss and neurodegeneration, which could represent a significant advancement in MS treatment.
The company is strengthening operational support for the program through a planned partnership with Allucent and engagement with neurological specialists. This strategic move is intended to enhance the development and execution of the upcoming Phase 2 trial. The positive Phase 1 results and IND submission mark important milestones for Quantum BioPharma as it seeks to bring a novel therapy to patients with MS, a chronic autoimmune disease affecting the central nervous system.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for challenging neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company is focused on the research and development of LUCID-MS, a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models.
In addition to its MS program, Quantum BioPharma invented unbuzzd and spun out its over-the-counter version to Unbuzzd Wellness Inc. (UWI), led by industry veterans. Quantum BioPharma retains ownership of 19.84% of UWI and is entitled to royalty payments of 7% of sales from unbuzzd until payments total $250 million, after which the royalty drops to 3% in perpetuity. The company retains 100% of the rights to develop similar products or alternative formulations for pharmaceutical and medical uses.
The advancement of LUCID-MS into Phase 2 trials represents a crucial step for Quantum BioPharma and offers hope for patients with multiple sclerosis who are in need of therapies that address the underlying cause of the disease. If successful, LUCID-MS could become a first-in-class treatment that directly targets myelin repair, differentiating it from current standard-of-care options.
For more information about Quantum BioPharma, visit the company’s newsroom at https://ibn.fm/QNTM.
